Bioengineered human heparin

Heparin is the most widely used anticoagulant in the treatment or prevention of blot clots. Heparin is sourced from animal tissues with issues of safety, supply and adverse events.

This project aims to develop a bioprocess for the scale production of heparin from human cells cultured in bioreactors. This work builds upon the team's patented technology and offers the market safety and stability of supply for the growing world market.

Project team

Associate Professor Megan Lord
Faculty of Engineering
Professor John Whitelock
Faculty of Engineering
Ms Ha Na Kim
Faculty of Engineering

Key contact

Faculty of Engineering
+61 2 9385 3910
m.lord@unsw.edu.au